Adalimumab therapy in children with Crohn disease previously treated with infliximab

Autor: Cozijnsen, M., Duif, V., Kokke, F., Kindermann, A., Rheenen, P. van, Meij, T. de, Schaart, M., Damen, G., Norbruis, O., Pelleboer, R., Neucker, A. van den, Wering, H. van, Hummel, T., Oudshoorn, J., Escher, J., Ridder, L. de, Dutch PIBD Working Grp Kids Crohn

Publikováno v: Journal of pediatric gastroenterology and nutrition, 60(2), 205-210. Lippincott Williams and Wilkins
Journal of Pediatric Gastroenterology and Nutrition, 60(2), 205-210. LIPPINCOTT WILLIAMS & WILKINS
Journal of Pediatric Gastroenterology and Nutrition, 60(2), 205-210. Lippincott Williams & Wilkins
Journal of Pediatric Gastroenterology and Nutrition, 60(2), 205-210
Journal of Pediatric Gastroenterology and Nutrition, 60(2), 205-210. Lippincott Williams and Wilkins
Cozijnsen, M, Duif, V, Kokke, F, Kindermann, A, van Rheenen, P, de Meij, T G J, Schaart, M, Damen, G, Norbruis, O, Pelleboer, R, Van den Neucker, A, van Wering, H, Hummel, T, Oudshoorn, J, Escher, J & de Ridder, L 2015, ' Adalimumab Therapy in Children With Crohn Disease Previously Treated With Infliximab ', Journal of Pediatric Gastroenterology and Nutrition, vol. 60, no. 2, pp. 205-210 . https://doi.org/10.1097/MPG.0000000000000589

Objectives: Adalimumab, a humanised anti-tumour necrosis factor antibody, is an effective treatment in adult patients with refractory Crohn disease (CD). The available literature on its efficacy in children remains limited. We aimed to evaluate the r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc10c8296711a7e7d918e665fbea5e60
https://doi.org/10.1097/mpg.0000000000000589